1. Proficient in processing singles, PCNS, Multiple packing, and vendor returns while maintaining quality and safety standards, ensuring timely order fulfillment.2. Experienced in training colleagues on multi-processing lines, stow, and vendor returns slam departments over the past 14 months.3. Actively involved in promoting safety as a First Aider on-site since July 2023, nominated for the safety executive committee tenure, emphasizing safety as a top priority at all times.

Focused on engaging NHS and private hospitals to utilize genetic services across major therapy areas such as cardiovascular, breast cancer, neurology, and gastrointestinal cancers. Provided market intelligence to HQ, collaborated with private labs/hospitals, and spearheaded a hypercholesterolemia screening campaign. Secured 10 new private accounts, estimating a potential business value of £80-140k over the next 12 months, despite HIC's decision to exit the UK market.

National Health Service (NHS) Fit TesterContractDepartment of Health and Social CareLondon, England, United KingdomHealth, Safety, and Environment (HSE) British Safety Industry Federation Accredited ( INDG 479 ) Fit2Fit FFP3 Tester, ensuring frontline NHS staff in South London/Medway NHS Trusts were fitted with appropriate PPE. Aligned with hospital and community infection control, prioritizing health, safety, and environment standards.

A newly established company specializing in pharmaceuticals and medical devices sourced from Eastern and Western European markets, with a focus on generics, class 2A OTC devices, and microbiome-based food supplements for the NHS and private sector gastro/obesity markets in the UK. Dedicated to obtaining market approval and registering products through MHRA agencies, while also overseeing product recruitment and marketing campaigns through external media agencies and deploying sales teams in the field. Additionally, actively involved in market intelligence gathering, pricing negotiations with wholesalers, pharmacy chains, and NHS trust customers, leveraging key opinion leader endorsements to secure reimbursements via trials and CCG reimbursements.

• Promoted Feraccru oral iron treatment for anaemia in Inflammatory Bowel Disease.• Established strong relationships with primary care/CCG/Secondary Care Trusts, securing reimbursement.• Facilitated medical advocacy and KOL plans, integrating customer-facing activities.• Analyzed funding streams and patient flows to increase Feraccru usage.• Achieved highest pack rate growth and rapid pull-through sales.• Nominated for ECCO Conference, enhancing awareness of IBD in patient outcomes.

• Executed sales plans for Johnson & Johnson's One Touch Blood Glucose Monitors in primary and secondary care markets.• Collaborated with sales team to implement account plans, driving performance and market share across diverse customer base.• Positioned Johnson & Johnson as industry leader through analysis, advocacy, and NHS training, engaging stakeholders and leveraging marketing materials for optimal visibility.• Led successful hospital engagements, trials, and formed partnerships with Lloyds Pharmacy Group, while producing formulary guidelines for increased market penetration.

• Efficiently managed a team overseeing projects for promoting 3 products in the Diabetes/Respiratory therapy sector, achieving formulary status on London APC for SGLT-2 in May 2015, alongside new launches. • Spearheaded the development and implementation of Diabetes/Respiratory awareness referral pathways project in Greenwich/Bromley CCG, reducing hospital admissions by optimizing drug usage guidelines.• Provided education and sponsorship for Type 2 Diabetes/COPD management, enabling nurses to gain prescriber status and organized a National Diabetes & Respiratory Day Course for 400 pharmacist delegates on behalf of UKCPA.• Collaborated with healthcare professionals to maximize Trajenta and Spiriva Respimat COPD market share impact, including formulary inclusion in teaching hospitals and developing key opinion leader relationships.• Achieved significant growth in Trajenta national market share by matching cash sales for SEL vs SWL and sustaining £1.0 million regionally for Spiriva (COPD) plus Spiolto launch, ranking as the 2nd highest performing region nationally for Diabetes market-based sales growth and market share.• Deputized for a team of 6 and reported to the Regional Director for 8 months before restructuring.

• Implemented a referral pathway for GP guidelines on hypertension management, collaborating with key opinion leaders from Queen Elizabeth Hospital (QEH).• Providing essential market insights for business development initiatives • Demonstrated exceptional business development skills, consistently exceeding sales targets and winning high-performance awards.• Actively participated in courses on Negotiations, Influencing Styles, and KOL Recruitment to enhance skills and knowledge.• Organized and facilitated trials, ensuring accurate data measurement and collaboration with internal MSL colleagues.• Recognized with awards for achieving company-defined metrics and fostering growth of the Olmetec range.• Therapy Review Specialist in hypertension, contributing to business growth and making recommendations based on 10 reviews within the territory.• Engaged in joint promotion with Merc-E Pharmaceuticals for their diabetes range, Glucophage SR.• Achievements : ABM/NHS champion, Daiichi Sankyo Value Sales Award, triple achievement in Olmetec Sales Performance, and ranking as the 2nd highest national sales for the Cetraben brand in dermatology.

Ranked 2nd in sales for the Synagis promotional campaign among 14 colleagues.Received Representative of the Month award in August 1998.Recognized as the Top Representative for Pharmacy Retail Orders in October 1998.